Neoprobe (NYSE Amex:NEOP) has reached an agreement to license imaging technology from Naviscan.
Dublin, Ohio-based Neoprobe will use Naviscan’s technology in conjunction with its own gamma-detection systems, which are used to evaluate the potential spread of cancer to lymph node tissues and organs, according to a statement from San Diego-based Naviscan.
The combined technology will translate gamma data into a 3-D image of a gamma-emitting source, such as a malignant lesion or tumor that has been injected with a radioactive tracing agent. The combined technology could enable surgeons to more precisely target cancerous lymph nodes for removal.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“We believe the three-dimensional gamma imaging technology from Naviscan is a natural extension of our current line of gamma-detection devices and enhances the opportunities in this technology category,” said Mark Pykett, Neoprobe’s chief development officer.
Pykett said Naviscan’s technology could lead to new applications for products Neoprobe is developing: Lymphoseek, a radio-pharmaceutical tracing agent that identifies cancerous lymph nodes in patients with breast cancer and melanoma, and RIGScan, a similar agent that would be used in colorectal cancer surgeries.
Lymphoseek could be on the market as soon as the end of this year, but RIGScan is several years away.
